Express Scripts Holding Co

Express Scripts — Caremark RX — Merger or Acquisition (January 2007)

19 slides from Express Scripts's merger presentation, Jan 24, 2007

  1. Slide 1: ESRX: Building on Proven Value Through Innovation and Execution

    ESRX: Building on Proven Value Through Innovation and Execution January 2007

  2. Slide 2: ESRX: Building on Proven Value

    ESRX: Building on Proven Value Proven history of producing value through innovation and execution Core profit generators hitting on all cylinders Growth potential remains strong, with wind at our back Current PE ratio historically low for comparable growth ESRX is bullish on the industry, and on its

  3. Slide 3: The Pharmacy Landscape

    The Pharmacy Landscape Retail Pharmacy Rx Wholesaler/ Generic Mfg Pharmaceutical Manufacturer Home Delivery Creates retail networks and obtains retail discounts Develops formularies and obtains manufacturer discounts Negotiates with generic manufacturers and wholesalers Operates home delivery pharma

  4. Slide 4: How We Make Money

    How We Make Money Multiple sources of margin for ESRX ESRX continues to have multiple and dynamic sources of margin, primarily fueled by generics, home delivery and specialty Rxs Brand in retail Brand in mail Specialty Generic in retail Admin fee Program fees Spread Rebate & admin fee sharing ALIGNM

  5. Slide 5: ESRX Growth Powered by Innovation and Execution

    ESRX Growth Powered by Innovation and Execution Ongoing innovation and execution in a dynamic environment help fuel ESRX's growth 1990 '91 '92 '93 '94 '95 '96 '97 '98 '99 2000 '01 '02 '03 '04 '05 '06 '07 East 3 6 7.4 21.9 31.1 49.1 66.2 84.9 135.4 243.1 288.5 357.4 439.6 479.4 517.5 563.3 West 30.6

  6. Slide 6: Generics

    Generics Greater use of generics can save more than $20B each year ESRX applies innovative thinking and an independent business model to deliver results Lipitor Crestor Vytorin Generics* ESRX -0.22 0.0515 0.0454 0.123 National -0.087 0.022 0.025 0.04 * Represents the portion of Lipitor share that wa

  7. Slide 7: Specialty - Biogenerics

    Specialty - Biogenerics Creation of biogenerics pathway will unlock $70B+ over next decade Opportunities in specialty opportunities are large and growing for PBMs who innovate and execute effectively on behalf of plan sponsors Impact of biogenerics pathway Class EPOs for anemia Insulin Interferons f

  8. Slide 8: Express Scripts Historical Forward P/E

    Express Scripts Historical Forward P/E Express Scripts is trading at a significant discount to historical P/Es

  9. Slide 9: ESRX: Building on Proven Value

    ESRX: Building on Proven Value Proven history of producing value through innovation and execution Core profit generators hitting on all cylinders Growth potential remains strong, with wind at our back Current PE ratio historically low for comparable growth ESRX is bullish on the industry, and on its

  10. Slide 10: ESRX and CMX: Accelerating the Generation of Value Through Innovation and Execution

    ESRX and CMX: Accelerating the Generation of Value Through Innovation and Execution

  11. Slide 11: Transaction Update

    Transaction Update Express Scripts launched a $25 billion Exchange Offer to acquire Caremark, which will deliver superior value to stockholders Fully committed financing provided by Citigroup and Credit Suisse Filed for HSR approval and confident that regulatory requirements will be met in a timely

  12. Slide 12: ESRX / CMX Transaction is in the Best Interests of Stockholders, Plan Sponsors, and Patients

    ESRX / CMX Transaction is in the Best Interests of Stockholders, Plan Sponsors, and Patients Solid strategic rationale Retains focus on proven profit generators: generics, mail, specialty Delivers rapid and straightforward synergies, not speculative ones Puts stockholders, clients and members first

  13. Slide 13: Conflicts Inherent to Retail Ownership

    Conflicts Inherent to Retail Ownership Vertical integration with retail introduces conflicts of interest and threatens savings Retail Drug choice Drug utilization Channel choice Overall retail discounts Fundamental business model Likely to be biased towards higher priced drugs Maximize number of fil

  14. Slide 14: Market Punishes PBMs that Lack Independence

    Market Punishes PBMs that Lack Independence History validates the independent model Lilly 1994 Rite Aid 1999 Advance 2000 SmithKline 1994 ESRX 1999 Merck 1993 Spin-off 2003 Change in Value - - 63% - - 34% - - 70% 21% (2% APR) AVG LOSS IN VALUE - - 36% $4.1B $1.5B $1.0B $2.3B $0.7B $6.5B $7.9B Transa

  15. Slide 15: CVS / CMX Scheme Unlikely to Work

    CVS / CMX Scheme Unlikely to Work "Between 2004 and 2010 the supply of all community pharmacists is expected to increase only 7.8% vs an estimated 27% increase in number of prescriptions dispensed." - NACDS "Industry Facts at a Glance"; Jan 23rd, 2007 Average length of time to recruit a pharmacist i

  16. Slide 16: Best and Brightest Innovating for Continued Growth

    Best and Brightest Innovating for Continued Growth Powerfully positioned to meet challenges Specialty: how to deal with expensive therapies with modest health benefits? Personalized medicine: how to manage drugs tailored for individuals? Consumerism: how to meaningfully activate patients to become s

  17. Slide 17: ESRX and CMX: The power of independence and proven value generation

    ESRX and CMX The power of independence and proven value generation Powerful strategic rationale Identifiable and achievable synergies Strong free cash flow and rapid debt reduction Superior currency and certainty of value Management team with history of earnings growth, superior stockholder returns,

  18. Slide 18: Forward-looking statements

    This presentation contains "forward-looking statements," including, among other statements, statements regarding the proposed business combination between Express Scripts and Caremark, and the anticipated consequences and benefits of such transaction. Statements made in the future tense, and words s

  19. Slide 19: Safe Harbor: Forward Looking Statements

    Safe Harbor: Forward Looking Statements IMPORTANT INFORMATION Express Scripts has filed a preliminary proxy statement in connection with Caremark's special meeting of stockholders at which the Caremark stockholders will consider the CVS Merger Agreement and matters in connection therewith. Express S

Caremark RX — Merger or Acquisition (January 2007) on 6ix